BioAxis Research
News
2024
Message Passing Neural Networks (MPNNs) for Molecule Property Prediction deployed. Models built for Toxicity/Property prediction
2023
Collaboration work continues, further new work in UK & NL, EuroStars application succesful
2022
Collaboration work continues with various clients, new UK and NL clients
2021
Collaboration work continues with various clients, new UK client
2020
Collaboration work continues with small biotechs, EU & US pharma, EU chemistry providers & screening centers, new work with UK charities
2019
Collaboration work continues with small biotechs, EU & US pharma, EU chemistry providers & EU screening centers
2018
Collaboration work continues and now includes small biotechs, EU & US pharma, EU chemistry providers & EU screening centers
Q3-4 2017
The International Chemical Design Course at RadboudUMC has taken place, including lectures and hands-on KNIME practicals given by BioAxis Research and the 3D-e-Chem consortium.
Collaboration work continues and now includes small biotechs, EU & US pharma, EU chemistry providers & EU screening centers
Q2 2017
BioAxis Research has recieved subsidy funding for a project "Multi-Target Metabolic Syndrom Drugs" (STIMULUS funding, MKB Innovatiestimulering topsectoren Zuid-Nederland).
Collaboration work continues and now includes small biotechs, EU & US pharma, EU chemistry providers & EU screening centers
Q1 2017
The 3D-e-Chem consortium, a team of cheminformatics and bioinformatics researchers from Centre for Molecular and Biomolecular Informatics, Netherlands eScience Center, BioAxis Research, and Vrije Universiteit Amsterdam have developed a freely available virtual machine to enable computer-aided drug design. The 3D-e-Chem software tools and virtual machine are described in a recent publication in the Journal of Chemical Modeling and Information and the computational building blocks (nodes) that enable researchers to design their own drug discovery workflows are now incorporated in KNIME, the leading open data analytics platform.
Tools and worflows developed by the 3D-e-Chem consortium were also presented and a workshop given at the KNIME Spring Summit in Berlin
Q4 2016
COILED collaboration funded by an EFRO grant begins
Collaboration work continues with small biotechs/large pharma/European screening centers
Q3 2016
Collaboration work continues with small biotechs/large pharma/European screening centers
Q1/Q2 2016
3d-e-Chem poster presented at Knime Spring Summit detailing progress on 3d-e-Chem Virtual Machine and Knime nodes
Ongoing collaborations continue with small biotechs are extended. New collobrations with Big Pharma begun
Q3/Q4 2015
Chemical Analytics Platfrom made available
Thanks to work performed by Stefan Verhoeven at the Netherland eScience center, a Vitual MAchine encompassing the work performed on the Chemical Analytics Platform project is now available on Github
Ongoing collaborations continue, are extended
Q1/Q2 2015
Ongoing collaborations continue, are extended
Q4 2014
Netherlands e-science center project "3D-e-Chem: Integrated eScience workflow to translate biological and chemical data into structure-based protein-ligand polypharmacology prediction", headed by Dr. C. de Graaf, (VU University Amsterdam) involves BioAxis Research (Link to VU News item, Dec 17 2014).
October 2nd, 2014 Exclusive R&D collaboration BioAxis Research and Okklo Life Science
Today BioAxis Research and Okklo Life Sciences have entered into an exclusive collaboration for R&D projects.
Their OCTOPlex technology contributes to the rapid development of specific sugar molecules, cyclodextrins, as potential treatment for various diseases.
BioAxis Research BV and Okklo Life Sciences BV have unique expertise on the design and development of cyclodextrin-based medicines. Cyclodextrins are ring-shaped sugar molecules with many promising features for development of new treatments, including therapies for rare (orphan) diseases. With the OCTOPlex technology, Okklo Life Sciences and BioAxis can rapidly design and optimize these molecules and develop these into potential therapeutics. In addition, the technology enables the design of novel cyclodextrins that can ‘inactivate’ a wide variety of drugs or harmful biological metabolites.
A first project will be initiated in the coming weeks, and other projects are planned for early 2015.
“With this agreement we strengthen our collaboration, and increase the capabilities of the technology. By working together, we will be able to more rapidly and effectively design and deliver drug candidates with the appropriate properties “ according to Ross McGuire, managing director of BioAxis Research.”We have successfully collaborated in the past and are very keen to demonstrate the strength of this combination again” said Daniel Zollinger, co-founder and managing director of Okklo Life Sciences.
BioAxis Research BV and Okklo Life Sciences BV are privately held companies, located at the Pivot Park in Oss, The Netherlands. Both enterprises have their roots in the former R&D organization of Organon/MSD and were involved in the development and approval of the first cyclodextrin-based drug in 2008.
Ongoing collaborations continue, are extended
Q3 2014
BioAxis Research involved in delivering the cheminformatics element of this project, using Open source relational databases, cheminformatics tools and analytics workflow management tools.
Ongoing collaborations continue, are extended
Publications updated
Q2 2014 Ongoing collaborations continue, are extended
Q1 2014 Ongoing collaborations continue, are extended
December 2013
Publications updated
November 2013
Publications updated
September 2013
BioAxis Research begins collaboration with a second European screening centre, extends other collaboratiions
BioAxis Research has begun working with another European screening centre, providing cheminformatics analyses and services. Work continues with existing clients, extensions to collaboration agreements having been made
July 2013
BioAxis Research signs NDA, begins collaboration
BioAxis Research has signed further confidentiality agreements with a European research consortium and has begun exploratory collaborations
July 2013
Publications updated
Mar 2013
Bioaxis Research extends agreement
BioAxis and a small biotech partner have agreed to extend an ongoing collaboration for a further period
December 2012
BioAxis Research Agreement with Vivenics
BioAxis and Vivenics have entered an agreed working arrangement concerning areas of common interest in infrastructure and workflow tools, details not disclosed
May 2012
BioAxis Research extends collaborations with 2 partners
BioAxis has extended a collaboration with one public:private group for a fixed period, while another commercial parter has extended an ongoing collaboration
April 2012
BioAxis Research Radboud University
R. McGuire is now offically associated with the UMC St Radboud Nijmegen Centre for Molecular Life Sciences
April 2012
BioAxis Research Moves to Oss Life Science Park
BioAxis Research has moved into offices in the Oss Life Science park, as of 2 April 2012.
March 2012
Publications updated
BioAxis Research has contributed to recent publications - see publications page.
October 2011
BioAxis Research signs CDA's, begins collaborations
BioAxis Research has signed a number of confidentiallity agreements with various European research groups and has also concluded negotiations to collaborate with and perform work for a number of research organizations.
September 15th 2011
BioAxis Research presents at 9th Annual World Pharmaceutical IT Congress
BioAxis Research gave an invited presentation on Open Source Cheminformatics and IT in Discovery research at the 9th Annual World Pharmaceutical IT Congress, London
October - November 2011
BioAxis Research further 2011 publications accepted
The latest publication to be accepted is a review on structure-based pharmacophores, co-authored with colleagues from MSD and Dutch academia, recently accepted for publication in MedChemComm. Recent publications will be listed in the publications page
October 2011
BioAxis Research operational
BioAxis Research was launched officially in October 2011. BioAxis Research BV is a privately funded start-up, founded by Ross McGuire, former head of in silico Drug Design, MSD Oss. The company has been in preparation for a few weeks and is already in discussions with potential partners
